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Hypoglycemia is one of the most important complications of diabetes treatment. The risk of severe hypoglycemia is
higher in elderly patients, those having comorbidities such as vascular disease or renal failure, pregnant women and
in children with type 1diabetes. Moreover, in type 2 diabetes, progressive insulin deficiency, longer duration of
diabetes, and tight glycemic control increase the risk of hypoglycemia as much as type 1 diabetes.Episodes
hypoglycemia may lead to impairment of counter-regulatory system, with the potential of development of
hypoglycemia unawareness. So, hypoglycemia may increase the vascular events even death in addition to other
possible detrimental effects. Glycemic control should be individualized based on patient characteristics with some
degree of safety. Recognition of hypoglycemia risk factors, blood glucose monitoring, selection of appropriate
regimens and educational programs for healthcare professionals and patients with diabetes are the major issues to
maintain good glycemic control, minimize the risk of hypoglycemia, and prevent long- term complications.
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Diabetes is a chronic disease that requires continuous
medical care and patient self-management education to
prevent acute complications and reduce the risk of long-
term complications [1]. The prevalence of diabetes has
reached epidemic proportions in most populations.
According to the UN World Health Organization (WHO)
more than 220 million people worldwide have diabetes,
from which more than 70% live in low- and middle in-
come countries. It is expected that the number of diabetic
subjects grows to 366 million by 2030, a figure that is
more than twice the number in 2000. Epidemiologic evi-
dences suggest that unless effective preventive measures
are implemented the global prevalence will continue to
rise [2].
In Middle East, internationally published data on na-
tional estimation of type 2 diabetes prevalence are spare.
In Iran a prevalence of 7.7% in people younger than
65 years is reported [3]. Diabetes and its complications
place a very heavy burden on health care systems. A study
in our country showed that the burden of diabetes and its
complications in term of Disability-Adjusted Life Years* Correspondence: emrc@tums.ac.ir
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reproduction in any medium, provided the or(DALYs) was 306,440 years [4]. All these points stress that
prevention of this disease and its complications is import-
ant in Iran.
The overall objective of type 2 diabetes’s management is
to achieve and maintain blood glucose control and reduce
the risk of long-term complications. Many studies have
shown that modern management with intensive glycemic
control can limit, delayed or even prevent the chronic
complications of diabetes. However this intensive diabetes
treatment could be associated with an increased risk of
hypoglycemia [5], particularly in patients with type 1 dia-
betes mellitus and patients with longstanding insulin-
treated type 2 diabetes mellitus [6-9].
Hypoglycemia is a true medical emergency which
requires prompt recognition and treatment to prevent
organ and brain damage. The spectrum of symptoms
depends on duration and severity of hypoglycemia and
varied from autonomic activation to behavioral changes to
altered cognitive function to seizures or coma. The short
and long term complications include neurologic damage,
trauma, cardiovascular events and death [10]. Severe un-
treated hypoglycemia can cause a significant economic
and personal burden, therefore identification and preven-
tion of hypoglycemia can reduce diabetes burden by pre-
vention of hypoglycemia complications.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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erature on impact of hypoglycemia on diabetes manage-
ment and try to provide guidance to health care providers
to safely and effectively assist the diabetic patients.
Epidemiology
For diabetic patients hypoglycemia is a fact of life. Ap-
proximately 90% of all patients who receive insulin have
experienced hypoglycemic episodes. The reported inci-
dence of hypoglycemia varies considerably among studies,
however in general patients with type1 diabetes have an
average of two episodes of symptomatic hypoglycemia per
week and one episode of severe hypoglycemia once a year.
An estimated 2–4% of deaths of this population have been
attributed to hypoglycemia [11,12].
It should be noted that the incidence of reported
hypoglycemia is usually under- estimates because of diffi-
culty to determine. The detection of hypoglycemia would
require continuous blood glucose measurements. In this
regard asymptomatic episodes of hypoglycemia could be
missed unless detected by monitoring of blood glucose.
On the other hand, the incidence of symptomatic episodes
is difficult to determine because they are rarely reported.
Additionally in some clinical trials hypoglycemia is not a
primary outcome which makes it difficult to estimate the
incidence of hypoglycemia. While the episodes of severe
hypoglycemia are a small fraction of the total hypo-
glycemic, estimation of this event is the most reliable since
severe hypoglycemia events are better documented [13].
The frequency of hypoglycemia is lower in people with
type 2 diabetes than Type 1 [12]. The UK Hypoglycemia
Study showed that in patients with type 2 diabetes the risk
of severe hypoglycemia is low in the first few years (7%)
and that risk increases to 25% later in the course of dia-
betes [14]. However the prevalence of type 2 diabetes is
about twenty fold higher than type 1 diabetes and many
patients with type2 diabetes finally require treatment with
insulin, therefore most episodes of hypoglycemia occur in
patients with type 2 diabetes.
The incidence of hypoglycemia also could be affected by
how tight glycemic control is performed. The Action to
Control Cardiovascular Risk in Diabetes (ACCORD)
reported a threefold increase in severe hypoglycemia and
coma in intensively treated patients versus conventionally
treated patients [15].
Pathophysiology
Glucose is an obligate metabolic fuel for the brain under
physiological conditions. Because the brain cannot syn-
thesize glucose, maintenance of brain function requires a
virtually continuous supply of glucose from the circula-
tion. In normal situation redundant glucose counter-
regulatory mechanisms effectively prevent or rapidly
correct hypoglycemia [13].When hypoglycemia happens, a decrease in insulin se-
cretion is the first response. Other hormones including
glucagon and epinephrine are also secreted promptly after
falling plasma glucose levels and both induce a rapid in-
crease in glucose production [16].
Hypoglycemia typically arises when abnormalities in the
mechanisms involved in glucose homeostasis is existed. In
patients with type 1 diabetes secretion of both counter-
regulatory hormones of insulin and glucagon is severely
interrupted. The third defense mechanism, the epinephrine
response to hypoglycemia, is also become progressively
impaired in type1 diabetic patients [17]. The frequent
bouts of hypoglycemia further reduce the sympathoadrenal
glycemic threshold to a lower plasma glucose level particu-
larly in patients with an intensive regulation of diabetes
[18]. The combination of glucagon absence and the attenu-
ated epinephrine response causes the clinical syndrome of
defective glucose counter- regulation, a syndrome that has
been shown to increase the risk of severe hypoglycemia by
25- fold or even higher during strict treatment compared
to when a normal epinephrine responses is presented [19].
Decreased in epinephrine response to hypoglycemia is a
marker of an attenuated autonomic neural response that
causes the clinical syndrome of hypoglycemia unawareness,
[20], a situation that in turn could increases the risk of se-
vere hypoglycemia development.
Hypoglycemia-associated autonomic failure (HAAF) in
type1 diabetes apparently results from recent antecedent
hypoglycemia that caused by both defective counter-
regulatory response and hypoglycemia unawareness. Thus
hypoglycemia caused HAAF may play a role in the vicious
cycle of recurrent hypoglycemia [12,21].
The mechanisms of defect in glucose counter-regulation
in type 2 diabetes are the same as type 1diabetes which
includes both defect in hypoglycemia counter-regulation
mechanism and deficiency of sense of hypoglycemia [6].
Similar to type 1 diabetes intensive therapy could lead to
development of defective counter-regulatory responses.
A study revealed that individuals with type 2 diabetes de-
velop defects in counter-regulatory responses to hypogly-
cemia after exposure to a single episode of hypoglycemia.
These patients can also develop blunted physiological
defenses to hypoglycemia following intensive oral therapy.
This suggests that people with type 2 diabetes who are
strictly treated are more likely to develop impaired
hypoglycemia awareness [22].Causes and risk factors for hypoglycemia
In general, hypoglycemia in diabetic patients occurs when
an imbalance between insulin/hypoglycemic agent’s intake
and body’s physiological need exists. The following rea-
sons could account for hypoglycemia in diabetics: Iatro-
genic, Diet changes and infections.
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eas are among the most common causes of hypoglycemia
in diabetic subjects [23]. The longer-acting sulphonylureas
such as glibenclamide and chlorpropamide are associated
with more severe hypoglycemia than the shorter-acting
drugs [24]. Occasional episodes of hypoglycemia with
Metformin, as the most commonly used anti-diabetic
drug, are reported when an imbalance between food in-
take and dose of Metformin is presented [25].
Hypoglycemia may also result from little foods intake or
increase in activity in relation to medication and food in-
take. Other causes such as alcohol consumption, some
drugs, stress and infections should also be considered in
diabetic subjects. Alcohol may contribute to the severity
of hypoglycemia by inhibiting gluconeogenesis.
Hypoglycemia could also be a symptom of severe organ
illnesses. Liver diseases such as hepatitis and cirrhosis as
well as kidney diseases often cause hypoglycemia, mostly
because of the major role that these organs play in glucose
production and maintenance blood sugar levels.
Hypoglycemia unawareness and a history of previous se-
vere hypoglycemia episodes are risk factors for severe
hypoglycemia. Impaired symptomatic awareness is asso-
ciated with a 6-fold and 9-fold increased risk of severe
hypoglycemia in patients with type1 and type 2 diabetes
respectively [8,20]. Patients receiving intensive insulin
therapy are at increased risk of hypoglycemia despite lack
of other risk factors.
In type 2 diabetes progressive insulin deficiency and
duration of insulin therapy increase the risk of
hypoglycemia as in type 1 diabetes, and the risk of
hypoglycemia is highest in those with type 2 diabetes who
have received insulin for more than 10 years [7]. Moreover
risk of severe hypoglycemia is higher in elderly patients,
those with co-morbidities such as vascular disease or renal
failure, pregnant women and in children with type 1dia-
betes [7,26].
Hypoglycemia and pregnancy
Pregnancy is associated with a high risk of severe hypo-
glycemia in diabetic subjects. Hypoglycemia in pregnant
women may lead to severe morbidity and even death [27].
In women with diabetes severe hypoglycemia episodes
occur three to five times more frequently in first trimester
than last trimester [28,29].
Although intensive metabolic control can prevent dia-
betic complications in pregnant woman and her offspring,
it may increase the risk of hypoglycemia [28]. History of
previous hypoglycemia in the year preceding pregnancy,
hypoglycemia unawareness, long duration of diabetes,
and fluctuation in glucose levels, have been documented
as risk factors of severe hypoglycemia during pregnancy
[28-30]. Pregnancy itself is associated with suppression of
glucose counter- regulatory responses. The exact mechanismfor this suppression is unclear; however some studies
have shown that reduced sympathoadrenal responses
during hypoglycemia may contribute to defective glu-
cose counter-regulation and impaired awareness of
hypoglycemia [31,32].
Tight metabolic control with focus on reduction of glu-
cose fluctuations during pregnancy improves the preg-
nancy outcome. Appropriate self-management training
including carbohydrate counting, hypoglycemia aware-
ness, and clear insulin dose adjustment instruction, are
important in diabetic-pregnant women in order to main-
tain near-normoglycemic state without episodes of severe
hypoglycemia particularly in early pregnancy stage.
Hypoglycemia in elderly
Hypoglycemia is a common problem in old people with
diabetes. Aging modifies the cognitive, symptomatic, and
counter-regulatory hormonal responses to hypoglycemia
[33]. The effect of aging on increased risk of unawareness
or severe episodes of hypoglycemia has also been recog-
nized [34]. Although hypoglycemia in the elderly is the
most common complication of tight glycemic control,
multiple co-morbidities like renal impairment, chronic
heart disease, malnutrition and polypharmacy may in-
crease risk of this complication [34].
In the elderly subjects, episodes of hypoglycemia are
more likely to be followed by changes in the blood brain
circulation which may further increase the risk of neuro-
logical damage in this population [35,36].
Severe hypoglycemia has a considerable impact on well-
being, productivity and quality of life in old people with
diabetes [37]. Management goals for elderly patients
should be an individualized process and must include a
number of considerations. Numerous studies have dem-
onstrated the benefits of avoiding intensive attenuation of
HbA1C to prevent severe hypoglycemia. Patient training
and treatment of the early symptoms of hypoglycemia
may prevent the occurrence of further severe hypo-
glycemia and decrease the rate of hospitalization, mortal-
ity and cognitive impairment that directly affects the
independence and functionality of older persons.
Hypoglycemia in children and adolescents
Hypoglycemia is one of the most common acute compli-
cations of insulin therapy in children and adolescents with
diabetes. The incidence of hypoglycemia is reported to be
between 3 and 27 episodes per 100 patient- year in chil-
dren with type 1diabetes [38]. The recurrent and severe
episodes of hypoglycemia cause hypoglycemic fearfulness
and emotional morbidity both for patients and their par-
ents, which could act as a limiting factor in achievement
of good glycemic control.
Impaired hypoglycemia awareness is a significant prob-
lem for children with type 1diabetes and a major risk
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Children with early-onset of diabetes, particularly those
diagnosed before age of 6, and severe episodes of hypo-
glycemia have an increased range of cognitive dysfunction
and brain abnormalities [40]. Repeated hypoglycemic sei-
zures in young children may also cause structural brain
changes [41].
Therefore regular glucose monitoring and detection of
the risk factors of hypoglycemia may help to reduce the
severity and frequency of hypoglycemia in children and
adolescent with diabetes.
Impact of hypoglycemia
Hypoglycemia can cause severe morbidity and even death,
usually depending on its severity or duration.
Hypoglycemia and vascular disease
A possible link between hypoglycemia and acute vascular
events like angina, myocardial infarction, and acute cere-
brovascular disease has been proposed by several studies
[42,43]. In addition some studies have highlighted an
increased risk of death and microvascular complications
when glucose levels are intensively controlled [15,44].
However some controversies exist in this issue. The
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial could not establish the direct role of
hypoglycemia in increased cardiovascular events [15],
while a much stronger link between severe hypoglycemia
and vascular events is indicated in the Veteran’s Affairs
Diabetes Trial (VADT) study [45]. Gimenez et al. [46]
suggested that repeated episodes of hypoglycemia may
promote the development of macrovascular disease in
type 1diabetes by increasing the risk of atherosclerosis.
Sympathoadrenal stimulation and release of counter-
regulatory hormones during acute hypoglycemia causes
hemodynamic changes including white blood cell activa-
tion and inflammatory mediators and cytokines release
[47,48]. Changes in regional blood flow, localized vasocon-
striction, an increased risk of intravascular coagulation
and endothelial damage, could provoke tissue ischemia
[49]. While chronic hyperglycemia is probably the main
driver of preclinical atherosclerosis in diabetes [50], recur-
rent exposure to hypoglycemia may contribute to this
process by aggravating established micro and macrovascu-
lar complications [51].
In addition hypoglycemia could potentially increase the
sudden death through inducing either ischemic or other
electrocardiographic changes (increased QTc), which in
turn may predispose the diabetic subjects to ventricular
arrhythmias [45,52].
Hypoglycemia and the brain
A new research suggests a possible association between se-
vere hypoglycemia and cognitive dysfunction. Åsvold et al.[53] suggested that early exposure to severe hypoglycemia
could have clinically relevant effects on cognition many
years later. In this study the overall cognitive scores of the
9 diabetic children who experienced severe hypoglycemia
before age of ten were lower than the eighteen diabetic
children without history of severe hypoglycemia. The
same result was evident when all children were re-
examined as adults 16 years later.
Many studies showed that the development of diabetes
in the first stages of life is associated with an increased risk
of neurocognitive dysfunction regardless of whether or
not severe hypoglycemia was present [54]. It has been
hypothesized that the diabetes-associated metabolic
changes may disrupt the process of normal brain develop-
ment in the first years of life. Severe hypoglycemia may
aggravate the severity of the brain dysfunction in people
with an early onset of diabetes [55,56]. Gaudieri et al.
found that risk factors for cognitive impairment in chil-
dren with diabetes include: hypoglycemia, duration of dia-
betes and poor glycemic control [57].
In type 2 diabetes, one longitudinal cohort study in eld-
erly patients revealed that severe hypoglycemia episodes
are associated with an increased risk of dementia in this
population, although the impact of mild episodes on de-
mentia risk remains unknown [58].
A recent study found that severe hypoglycemia causes
brain damage in cortex and the hippocampus regions and
the extent of damage was closely correlated to the pres-
ence of seizure-like activity. The results were indicative of
elevation of sensitivity of the cortex to the damaging
effects following an episode of severe hypoglycemia [35].
These researches remind us to be particularly alert for
the child or adult who experience severe hypoglycemia
early in life. This population is more likely to manifest de-
velopmental delays and cognitive dysfunction [54]. Their
reports of poor performance in school, or difficulties at
work may reflect CNS anomalies secondary to diabetes
and its treatment, and may be agreeable to various re-
mediation strategies [59].Hypoglycemia and quality of life
Studies reported that severe hypoglycemia can have a sig-
nificant impact on patients' health-related quality of life,
treatment satisfaction, and cost of diabetic management.
The wellbeing of patients may be affected both directly
from the effects of hypoglycemia and indirectly from fear
of recurrence [60,61]. Marret et al. found the positive as-
sociation between severity/ frequency of hypoglycemic
episode and greater fear of hypoglycemic events [62]. As a
result hypoglycemic fearness makes the patients to modify
their behaviors in a way to have less episodes of
hypoglycemia, which this in turn could contribute to a
negative glycemic control. Taken together these effects
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Prevention of hypoglycemia
While achieving and maintaining the optimal glycemic
control is one of the principal aims of prevention and
management of diabetes complications, hypoglycemia
remains a major challenge [63]. Obviously prevention of
hypoglycemia is preferable to its treatment since as com-
pared with a reactive approach, prevention is much more
likely to avoid severe events and economic burden. The
prevention of hypoglycemia requires some principles
consideration. These principles include: 1) diabetes self-
management (supported by education and empower-
ment); 2) self- monitoring of blood glucose or continuous
glucose sensing; 3) flexible and appropriate insulin or
other drug regimens; 4) individualized glycemic goals; 5)
consideration of known risk factors of hypoglycemia; 6)
professional support and guidance [64,65].
Diabetes self-management, supported by education and
empowerment, is a basic part of diabetes care to achieve
successful health-related outcomes [66,67]. Several studies
have found that diabetes self-management education
(DSME) results in behavior changes with positive influ-
ence on outcome [68,69]. Patients with diabetes need to
be well informed about the symptoms of hypoglycemia, to
know about hypoglycemia risk factors, prevention and
treatment, and to be concern about monitoring of blood
glucose levels. Therefore educating the patients of all ages
and their relatives about hypoglycemia is a key factor in
prevention of this complication.
In addition, blood glucose monitoring (BGM), using any
of the widely available self- monitoring blood glucose
(SMBG) or interstitial glucose sampling using continuous
glucose monitors (CGM); is an important part of manage-
ment of diabetes; especially for people who experience
hypoglycemic episodes [70]. BGM provides an immediate
evaluation of blood glucose levels; information that can be
used to guide the therapy and to detect the hypoglycemia,
and offers important feedback both to patients and to the
health cares about glycemic control and patient treatment
satisfaction [71]. CGM may be particularly important for
patients with hypoglycemia unawareness and/or patients
experiencing frequent episodes of hypoglycemia [72].
It is important that in patients with a history of recur-
rent hypoglycemia, the time of episodes be identified and
the treatment regimen be adjusted accordingly [65]. With
a basal-bolus insulin regimen, morning fasting hypo-
glycemia may be caused by the long- or intermediate- act-
ing insulin; daytime hypoglycemia is implicated by rapid
or short acting insulin; and nocturnal hypoglycemia may
be implicated by either. Substitution of short-acting (regu-
lar) insulin with rapid-acting insulin (e.g. lispro or aspart)
reduces frequency of daytime hypoglycemia. Substitutionof long-acting (e.g., glargine or determir) insulin for
intermediate- acting insulin (e.g., NPH or premix 70/30)
reduces frequency of nocturnal and daytime hypoglycemia
[65,73].
Continuous subcutaneous insulin infusion (CSII) with a
rapid-acting insulin analog improves the glycemic control
and reduces the rate of hypoglycemia compared with mul-
tiple daily insulin injection [74].
Patients on oral anti-diabetic drugs are also at risk
for developing hypoglycemia. Agents such as metformine,
dipeptidyl peptidase-4 inhibitors, and thiazolidines are
preferable to sulfonylureas in minimizing hypoglycemic
risks [13].
Glycemic goals should be individualized with some de-
gree of safety particularly for patients with long duration
of diabetes; patients who have a high risk of severe hy-
poglycemia development, and/or subjects with multiple
co-morbidities [11,75,76]. Individualized treatment should
be determined by a close working relationship between
diabetes care team and the patients. The health care pro-
fessionals may improve patient knowledge and produce
positive changes in life style and self-care decisions. The
diabetes care team involvement not only provides the ini-
tial patient’s guidance, but also monitors the short and
long term complications for early detection and manage-
ment [77,78].
Conclusions
Hypoglycemia is a major limiting factor in tight glycemic
management of diabetes and may increase vascular events
in addition to other possible detrimental effects. Glycemic
control should be individualized based on patient charac-
teristics with some degree of safety. Recognition of hypo-
glycemia risk factors, blood glucose monitoring, selection
of appropriate regimens, education programs for health-
care professionals and patients with diabetes are the major
issues to maintain good glycemic control, minimize the
risk of hypoglycemia, and prevent long- term complications.
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